JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weisel, R. D.
Right arrow Articles by Yau, T. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weisel, R. D.
Right arrow Articles by Yau, T. M.
Related Collections
Right arrow Molecular biology

J Thorac Cardiovasc Surg 2003;125:S53-S54
© 2003 The American Association for Thoracic Surgery

Editorials

Cell transplantation comes of age

Richard D. Weisel, MD, Ren-Ke Li, MD, Donald A. G. Mickle, MD, Terrence M. Yau, MD

From the Division of Cardiovascular Surgery, The Toronto Hospital, Toronto, Ontario, Canada.

Richard D. Weisel, Ren-Ke Li, and Donald A. G. Mickle are consultants to and receive research funding from the Genzyme Corporation, Cambridge, Mass.

Received for publication Feb 7, 2001. Accepted for publication Feb 9, 2001. Address for reprints: Richard D. Weisel, MD, FRCS, Division of Cardiovascular Surgery, The Toronto Hospital, 200 Elizabeth St, EN 14-215, Toronto M5G 2C4, Ontario, Canada (E-mail: Richard.Weisel@uhn.on.ca).

The first 20% of the full text of this article appears below.

The results of the first clinical experience with cell transplantation were reported to the American Heart Association in November 2000 by Menasche and associatesGo 1 of Paris. A 72-year-old man who had a transmural myocardial infarction with an ejection fraction of 21% received skeletal myoblasts implanted into the infarct region at the time of coronary bypass surgery. Five months later, he had recovered from the operation, and perfusion and function of the infarct region had improved, perhaps related to the cell transplantation. This initial case report provides hope that the damage from an extensive myocardial infarction may be reversed. Coronary bypass surgery is frequently inadequate to restore function in patients who have few viable surviving myocytes in the infarct region. Cell transplantation offers the promise of restoring function in these unfortunate patients.Go Go 2-4 However, the era of cell transplantation has only begun. Major questions remain. What type of cell is appropriate for autotransplantation? When should these cells be delivered and by what route? What is the efficacy of cell transplantation relative to other medical and surgical treatments? What outcome measures can . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.